Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on ...

Veranex, a global provider of product development and contract research services, today introduced the industry’s first ...

Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.

The year kicked off with a handful of acquisitions from top companies. Dealmaking has since slowed amid economic uncertainty ...

Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, ...

Johnson & Johnson (NYSE: JNJ) shares ticked up before hours today on second-quarter results that came in ahead of the ...

Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara ...

Three young Triangle-based medical technology companies with roots in Duke University research labs are getting major global attention from their industry. They’re among the 65 cutting-edge companies ...

Medical technology has been on the up for many years, and professionals and experts in Australia have been making strides in innovation over the last decade.

Johnson & Johnson MedTech today announced FDA approval for an update to its Varipulse platform's irrigation flow rate.

Steris (STE) stock and Solventum (SOLV) stock is upgraded, while RxSight (RXST) stock is downgraded at Morgan Stanley on valuations. Read more here.

J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.